JP2022525164A5 - - Google Patents

Info

Publication number
JP2022525164A5
JP2022525164A5 JP2021555282A JP2021555282A JP2022525164A5 JP 2022525164 A5 JP2022525164 A5 JP 2022525164A5 JP 2021555282 A JP2021555282 A JP 2021555282A JP 2021555282 A JP2021555282 A JP 2021555282A JP 2022525164 A5 JP2022525164 A5 JP 2022525164A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
concentration
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022535 external-priority patent/WO2020186132A1/en
Publication of JP2022525164A publication Critical patent/JP2022525164A/ja
Publication of JP2022525164A5 publication Critical patent/JP2022525164A5/ja
Priority to JP2025002888A priority Critical patent/JP2025061116A/ja
Pending legal-status Critical Current

Links

JP2021555282A 2019-03-14 2020-03-13 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 Pending JP2022525164A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002888A JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818189P 2019-03-14 2019-03-14
US62/818,189 2019-03-14
PCT/US2020/022535 WO2020186132A1 (en) 2019-03-14 2020-03-13 Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002888A Division JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Publications (2)

Publication Number Publication Date
JP2022525164A JP2022525164A (ja) 2022-05-11
JP2022525164A5 true JP2022525164A5 (https=) 2023-03-20

Family

ID=70228815

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555282A Pending JP2022525164A (ja) 2019-03-14 2020-03-13 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
JP2025002888A Pending JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002888A Pending JP2025061116A (ja) 2019-03-14 2025-01-08 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用

Country Status (9)

Country Link
US (1) US20200317815A1 (https=)
EP (1) EP3938404A1 (https=)
JP (2) JP2022525164A (https=)
KR (1) KR20210142006A (https=)
AU (1) AU2020237259A1 (https=)
CA (1) CA3133576A1 (https=)
MX (1) MX2021011110A (https=)
TW (1) TW202100561A (https=)
WO (1) WO2020186132A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4090427A1 (en) * 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
EP3387018A1 (en) * 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Similar Documents

Publication Publication Date Title
JP2022525164A5 (https=)
JP2022033868A5 (https=)
JP2020002171A5 (https=)
RU2650618C2 (ru) Комбинации и их применение
JP2021535161A5 (https=)
JP2021514969A5 (https=)
JP2019523295A5 (https=)
JP2018514510A5 (https=)
JP2003531129A5 (https=)
JP2024113183A5 (https=)
WO2016180958A1 (en) Treatment for multiple myeloma (mm)
JP2023527542A5 (https=)
JP2023510854A5 (https=)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2021523138A5 (https=)
JP2021532176A5 (https=)
JP2022514561A5 (https=)
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
JP2024540435A5 (https=)
CN116209443A (zh) 治疗小细胞肺癌的药物组合
JP2023546504A5 (https=)
JP2023544620A5 (https=)
JP2022547061A5 (https=)
RU2021129732A (ru) Ингибиторы плазменного калликреина и их применение для лечения приступа наследственного ангионевротического отека
JP2024522620A5 (https=)